Investors reacted positively to Lilly's (LLY)
first quarter earnings report, but there was actually little in the
news that impacts the long-term story here. Pressure on revenue and
margins is going to accelerate as the year moves on, and the company has
some make-or-break clinical data coming up. While bulls are right that
favorable data will push the shares considerably higher, there is a very
real chance that this stock could be yielding 6% or 7% in a year's
time.
Please read more here:
Lilly's Beat Doesn't Change The Long-Term Dilemma
No comments:
Post a Comment